



## Lexette® (halobetasol propionate) – Expanded indication

- On August 18, 2021, the [FDA approved](#) Mayne Pharma's [Lexette \(halobetasol propionate\)](#), for the topical treatment of plaque psoriasis in patients 12 years of age and older.
  - Lexette was previously approved for this indication in patients 18 years of age and older.
- The safety and effectiveness of Lexette in patients 12 to less than 18 years of age is supported by evidence from adequate and well-controlled studies in adults and from one open-label safety study in 24 patients aged 12 to less than 18 years.
- The recommended administration of Lexette for all patients is a thin uniform film to the affected skin twice daily for up to two weeks.
  - Therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of the diagnosis may be necessary.
  - Treatment beyond two weeks is not recommended and the total dosage should not exceed 50 grams per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.